Brief: JCR Pharmaceuticals - Chairman And President Transition As Of April 1, 2026
13/05/2025 08:08
May 13 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T: ANNOUNCES CHAIRMAN AND PRESIDENT TRANSITION AS OF APRIL 1, 2026 DIRECTOR HIROYUKI SONODA TO BECOME PRESIDENT EFFECTIVE APRIL 1, 2026 Source text: ID:nTSqm8582b Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results